Printer Friendly

FIRST COMPLETE STRUCTURE OF DISEASE FIGHTING ANTIBODIES SOLVED

 SHERMAN OAKS, Calif., Dec. 1 ~PRNewswire~ -- The first complete x-ray picture of an intact antibody, obtained by a team of scientists from ImmunoPharmaceutics Inc. (IPI) and the University of California at Riverside, has appeared in the new issue of the research publication Nature. Antibodies are the "magic bullets" that act as the key defense for humans and animals against disease caused by bacteria, viruses and cancerous cells. Although incomplete x-ray pictures had been obtained in the past, the team crystallized and analyzed a complete antibody showing that antibodies resemble a flexible assembly of three protein "rafts" tied to each other by two protein "ropes." Because the ends of two of the rafts become attached to the target, this unexpectedly flexible arrangement is likely to be an important factor in the ability of antibodies to attack a broad variety of intruders.
 Antibodies consist of three pieces, Edward T. Maggio, ImmunoPharmaceutics' chief executive officer explained. One piece, called the constant fragment, is the same for all antibodies. The two other pieces, the variable fragments, have different end structures, depending on the target that they neutralize. But it was believed that the variable fragments were connected to the constant fragments by two hinges, allowing the variable fragments to swing back and forth like doors, Maggio said. The new, raft-like structure is a far more flexible arrangement, he explained, and will aid IPI scientists in developing modified antibodies for disease treatment, diagnosis, and drug design.
 ImmunoPharmaceutics Inc. is 43 percent owned by Synbiotics Corp. (NASDAQ: SBIO). The company is developing a new class of drugs for the treatment of heart disease and asthma, as well as new drugs for inflammation and arthritis, its second strategic area. The IPI technology is based on the rational design of new drugs from antibody and protein structures, using x-ray crystallography and supercomputational methods.
 -0- 12~1~92
 ~CONTACT: Bill Coffin of Financial Relations Board, 818-784-7010, for ImmunoPharmaceutics~
 (SBIO)


CO: ImmunoPharmaceutics Inc. ST: California IN: MTC SU:

MS-LS -- LA015 -- 2308 12~01~92 10:01 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 30, 1992
Words:337
Previous Article:BERGEN BRUNSWIG ANNOUNCES FILING OF
Next Article:A-12 DEFERMENT AGREEMENT REVIEW TO BE COMPLETED DEC. 15
Topics:


Related Articles
LA JOLLA PHARMACEUTICAL'S PATENT ALLOWED
PROGENICS PHARMACEUTICALS AWARDED NIH GRANT FOR DEVELOPMENT OF SECOND-GENERATION AIDS VACCINE
IMMUNOGEN PUBLISHES RESULTS USING NOVEL ANTIBODY HUMANIZATION TECHNIQUE IN THE PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES
CANADIAN FIRM SIGNS MULTI-MILLION DOLLAR DEAL TO PARTICIPATE IN U.K. HUMAN ANTIBODY BREAKTHROUGH TECHNOLOGY
Medarex Receives Milestone Payment from Eisai Co., Ltd.
Oxford Glycosciences and Cambridge Antibody Technology announce strategic alliance in protein microarrays.
Coley Pharmaceutical Group Begins Phase I/II Trial of CpG 7909 in Combination with Herceptin (R) to Treat Breast Cancer.
Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's Patents and Patent...
Intellect Neurosciences Grants License to Certain Alzheimer's Patents and Patent Applications.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters